^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

PD-L1 negative

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
9d
A Case Report of Concurrent Epidermal Growth Factor Receptor (EGFR) Exon 18 (G719A) and Exon 21 (L833_V834delinsFL) Mutations and Treatment Challenges. (PubMed, Cureus)
The patient had two metachronous lung primary cancers resected in 2022 and 2024. Due to the complete surgical resection, the sensitivity of this mutation of TKIs could not be established. This unique mutation profile still remains of paramount importance to understand if the patient relapses or presents with a new tumor with the same genetic profile.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
EGFR mutation • PD-L1 negative • EGFR G719A
|
PD-L1 IHC 22C3 pharmDx
10d
E7389-J081-114: Study of E7389 Liposomal Formulation in Participants With Solid Tumor (clinicaltrials.gov)
P1, N=140, Active, not recruiting, Eisai Co., Ltd. | Trial completion date: Aug 2025 --> Mar 2026
Trial completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 negative • PD-L1 negative
|
eribulin liposomal (E7389-LF)
10d
Noninvasive Monitoring of Programmed Death-Ligand 2 Expression with Positron Emission Tomography using 68Ga-labeled Peptide Antagonist in Preclinical and Exploratory Human Studies. (PubMed, Research (Wash D C))
The results indicate a higher response rate to anti-PD-1 therapy in patients positive for both PD-L1 and PD-L2, with PD-L2 status independently predicting progression-free survival (PFS) with pembrolizumab treatment. Furthermore, [68Ga]Ga-HN11-1 PET imaging demonstrates specificity in assessing PD-L2 status. Overall, we confirm the correlation between high PD-L2 expression and favorable PFS in NSCLC patients post anti-PD-1 therapy and highlight the promising potential of [68Ga]Ga-HN11-1 as a specific tracer for PD-L2 in preclinical and initial human trials.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L2 (Programmed Cell Death 1 Ligand 2)
|
PD-L1 expression • PD-L1 negative • PD-L2 expression
|
Keytruda (pembrolizumab)
10d
Heterogeneity between subgroups of first-line chemoimmunotherapy for extensive-stage small cell lung cancer patients: a meta-analysis and systematic review. (PubMed, Front Oncol)
More trials are needed to prospectively validate the therapeutic heterogeneity among clinicopathological characteristics. https://inplasy.com/inplasy-2023-3-0064/ identifier, INPLASY202330064.
Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
15d
A Case of Granulocyte-Colony-Stimulating Factor-Producing Non-Small Cell Lung Cancer under Steroid Treatment and with Poor Performance Status That Responded to Pembrolizumab. (PubMed, Case Rep Oncol)
Thus, we initiated the administration of dexamethasone (3.3 mg/day). Pembrolizumab may be effective against G-CSF-producing NSCLC with high PD-L1 expression. Corticosteroids seemed to inhibit inflammation induced by the tumor, and exert the efficacy of pembrolizumab.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CRP (C-reactive protein)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative
|
Keytruda (pembrolizumab) • dexamethasone
16d
The Expression of PDL-1 and PD1 in the Microenvironment of Oral Squamous Cell Carcinoma. (PubMed, Asian Pac J Cancer Prev)
PDL-1/TILS and PDL-1/TC are independent prognostic factors in OSCC and PDL1-/TILS has an important role.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-L1 negative • PD-1 expression
16d
Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, Curr Gene Ther)
A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.
Clinical • Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Keytruda (pembrolizumab)
17d
Spontaneous Complete Regression of Breast Cancer: Two Case Report. (PubMed, Ann Ital Chir)
This situation suggests that breast surgeons, in particular, should conduct a thorough physical examination and, if necessary, re-radiological examination before surgery on patients for whom surgery is decided after diagnosis. Being careful in this regard may increase the number of SR in BC cases and allow molecular investigations on living tissue samples to reveal the underlying mechanism.
Journal
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
18d
Increased PD-1/PD-L1 Immune Checkpoint Expression Is Associated With Oral Squamous Cell Carcinoma in Never-Smokers and Never-Drinkers. (PubMed, Head Neck)
OSCC arising in never-smokers/never-drinkers exhibit heightened PD-1/PD-L1 signaling, suggesting potential efficacy of immune checkpoint therapy in this subgroup of tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1) • PD-L2 (Programmed Cell Death 1 Ligand 2)
|
PD-L1 expression • PD-L1 negative • PD-1 expression • PD-1 elevation
18d
Gut Microbiota as a Potential Biomarker for Immune Checkpoint Inhibitors (PubMed, Gan To Kagaku Ryoho)
Recently, attention has also been drawn to the lung microbiota and tumor microbiota in the context of lung cancer, with reports suggesting that increased diversity in these microbial communities may correlate with the efficacy of ICI therapy. However, none of these findings alone provide sufficient evidence as standalone biomarkers, necessitating future research to advance from both the host environment, including the gut microbiota, and the microenvironment of the tumor site, such as the lung and tumor microbiota.
Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
20d
Personalized Immunotherapy Achieves Complete Response in Metastatic Adenoid Cystic Carcinoma Despite Lack of Conventional Biomarkers. (PubMed, Curr Oncol)
Accordingly, we achieved a complete response in a radiotherapy (RT) and chemotherapy (CT)-refractory patient with locally recurrent lacrimal gland (LG) ACC and lung metastasis following personalized immunotherapy in combination with integrative therapeutics. Therefore, it is crucial to assess not only conventional immune biomarkers but also patient-specific parameters, especially in "immune-cold" cancer types.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Metastases
|
TMB (Tumor Mutational Burden) • NOTCH1 (Notch 1) • KDM6A (Lysine Demethylase 6A)
|
PD-L1 negative • TMB-L
22d
Clinical significance of CD155 expression in surgically resected lung squamous cell carcinoma. (PubMed, Int J Clin Oncol)
Our analysis revealed that high CD155 expression significantly predicted poor prognosis in patients with surgically resected LUSC, especially in patients with PD-L1-positive tumors.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • PVR (PVR Cell Adhesion Molecule)
|
PD-L1 expression • PD-L1 negative
23d
Trial termination • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)
24d
Exploration of efficacy of the first-line treatment for advanced non-small cell lung cancer with primary MET-amplification: Retrospective evaluation of 36 cases. (PubMed, Int Immunopharmacol)
Immuno-chemotherapy is a first-line optional treatment strategy in addition to targeted therapy for NSCLC patients with primary METamp. Foxp3-negative expression better predicts the near-term efficacy of immunotherapy.
Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • PD-1 (Programmed cell death 1) • FOXP3 (Forkhead Box P3)
|
PD-L1 expression • MET amplification • PD-L1 negative • FOXP3 expression
28d
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC (clinicaltrials.gov)
P2, N=24, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Oct 2024 --> Jan 2025
Trial initiation date • Checkpoint inhibition
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
28d
IRE1α silences dsRNA to prevent taxane-induced pyroptosis in triple-negative breast cancer. (PubMed, Cell)
Consequently, IRE1α RNase inhibitor plus taxane converts PD-L1-negative, ICI-unresponsive TNBC tumors into PD-L1high immunogenic tumors that are hyper-sensitive to ICI. We reveal IRE1α as a cancer cell defense mechanism that prevents taxane-induced danger signal accumulation and pyroptotic cell death.
Journal
|
IGF2BP1 (Insulin Like Growth Factor 2 MRNA Binding Protein 1) • ERN1 (Endoplasmic Reticulum To Nucleus Signaling 1) • NLRP3 (NLR Family Pyrin Domain Containing 3)
|
PD-L1 negative
28d
Trial completion date • Trial primary completion date • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
carboplatin • gemcitabine • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy)
30d
Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosis. (PubMed, Sci Rep)
In addition, compared with PD-L1-negative yolk sac tissue, dysgerminomas/seminomas with high PD-L1 expression are associated with more genetic alterations and a better prognosis. Our findings will contribute to the knowledge about the potential benefits of ovarian cancer immunotherapy in specific subsets of germ cell tumor patients and the risk factors for resistance mediated by tumor microenvironment cells.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 overexpression • PD-L1 negative
1m
Clinical • P2 data • Preclinical • Retrospective data • Review • Journal • Metastases
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • PD-L1 negative
|
Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)
1m
A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma (clinicaltrials.gov)
P2, N=30, Recruiting, Elizabeth Buchbinder, MD | Trial primary completion date: Sep 2024 --> Dec 2024
Trial primary completion date • Metastases
|
PD-L1 negative
|
Avastin (bevacizumab) • Tecentriq (atezolizumab)
1m
Clinical validation of a novel multi-omic algorithm for stratifying outcomes in a real-world cohort of metastatic solid cancer patients treated with immune checkpoint inhibitors (SITC 2024)
Ethics Approval Tempus AI, Inc. has been granted an IRB exemption (Advarra Pro00072742) permitting the use of de-identified clinical, molecular, and multimodal data in order to derive or capture results, insights, or discoveries.Download figure Open in new tab Download powerpoint Abstract 188 Figure 1
Checkpoint inhibition • Real-world evidence • Clinical • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker • Real-world • Metastases
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 negative • TMB-L
|
Tempus xT Assay • Tempus xR
1m
Exploration of different immunogenomic TMEs in gastric cancer based on HER2 and PD-L1 expression (SITC 2024)
Background Recent results from the KEYNOTE-811 study showed that first-line pembrolizumab was superior to placebo with respect to progression-free survival (PFS) in combination with trastuzumab and chemotherapy in patients with HER2 positive metastatic gastric cancer (GC). Conclusions The high proportion of CD4 Tregs, CD8 Tex and the elevated exhausted score in the subgroup with PD-L1 negative in HER2 positive GCs suggesting immune exclusive environment compared to HER2 and PD-L1 coexpressing group. Considering increased expression of immune checkpoint proteins other than PD-1/PD-L1, for patients with HER2-positive and PD-L1 negative, combination therapy with other immune checkpoint inhibitors rather than anti-PD-1/PD-L1 may be suggested.
PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD4 (CD4 Molecule) • BTLA (B And T Lymphocyte Associated)
|
PD-L1 expression • HER-2 positive • HER-2 negative • HER-2 expression • PD-L1 negative • LAG3 expression • HER-2 positive + PD-L1 expression • PD-L1 expression + HER-2 expression
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab) • Herceptin (trastuzumab)
1m
Pepinemab a semaphorin 4D blockade antibody in combination with immune checkpoint therapies induces mature lymphoid aggregates correlating with clinical outcomes (SITC 2024)
The KEYNOTE-B84 study (NCT04815720) evaluated the safety and efficacy of pepinemab in combination with pembrolizumab as a first-line treatment for immunotherapy-naïve patients with R/M HNSCC. Biomarker studies conducted in patients with surgically resectable metastatic melanoma (NCT03769155) and HNSCC (NCT03690986) received neoadjuvant treatment with pepinemab/nivolumab/ipilimumab combinations compared to nivolumab or ipilimumab alone...Increased density and maturity of lymphoid aggregates correlated with disease control and longer progression-free survival (PFS). Conclusions Pepinemab, a Semaphorin 4D (SEMA4D) blocking antibody, in combination with ICB converts 'Cold' tumors to 'Hot' by inducing organized lymphoid aggregates.
Combination therapy • Clinical data • Clinical • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • SEMA4D (Semaphorin 4D)
|
PD-L1 underexpression • PD-L1 negative • PD-L1-L • CXCR5 expression
|
Sema4 Signal®
|
Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • pepinemab (VX15)
2ms
An Unconventional Case Study of Neoadjuvant Oncolytic Virotherapy for Recurrent Breast Cancer. (PubMed, Vaccines (Basel))
Here, we describe the unique case of a 50-year-old self-experimenting female virologist with locally recurrent muscle-invasive breast cancer who was able to proceed to simple, non-invasive tumour resection after receiving multiple intratumoural injections of research-grade virus preparations, which first included an Edmonston-Zagreb measles vaccine strain (MeV) and then a vesicular stomatitis virus Indiana strain (VSV), both prepared in her own laboratory. The patient completed one-year trastuzumab adjuvant therapy and remains well and recurrence-free 45 months post-surgery. Although an isolated case, it encourages consideration of oncolytic virotherapy as a neoadjuvant treatment modality.
Journal • Oncolytic virus • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8)
|
PD-L1 expression • CD20 positive • PD-L1 negative • CD8 positive
|
Herceptin (trastuzumab)
2ms
Ovarian Mesonephric-like Adenocarcinoma: Its Prevalence in a Japanese High-Volume Cancer Center and a Literature Review on Therapeutic Targets. (PubMed, Curr Oncol)
MLAs accounted for 0.6% of malignant ovarian tumors at our institution, all of which were advanced or recurrent cases. These cases showed HRP, pMMR, and PD-L1 negativity, indicating a lack of current therapeutic targets. The literature also reported a high incidence of advanced and recurrent cases, highlighting the need for accurate diagnosis and the development of new treatments. The frequent KRAS mutations suggest a potential therapeutic target for recurrent or metastatic MLA.
Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • HER-2 expression • PD-L1 negative
2ms
Deep learning-based image analysis predicts PD-L1 status from 18F-FDG PET/CT images in non-small-cell lung cancer. (PubMed, Front Oncol)
After joint clinical feature modeling, the AUC and accuracy of predicting PD-L1 positive for PET/CT were 0.96 ± 0.00905 and 0.950 ± 0.0250, respectively. This study combines the features of 18F-FDG PET/CT images with clinical features using deep learning to predict the expression of PD-L1 in NSCLC, suggesting that 18F-FDG PET/CT images can be conducted as biomarkers for PD-L1 expression.
Journal • PD(L)-1 Biomarker • IO biomarker • FDG PET
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
2ms
Trial completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • magrolimab (ONO-7913)
2ms
Adjuvant immunotherapy in high-risk muscle invasive urothelial carcinoma: A systematic review and meta-analysis of randomized clinical trials. (PubMed, Urol Oncol)
Regarding subgroup analyses, there was significant benefit among patients with negative PD-L1 expression (HR 0.76, 95% CI 0.64-0.90), those who received prior NAC (HR 0.69, 95% CI 0.52-0.91), and patients with lower tract (HR 0.71, 95% CI 0.55-0.92) but not upper tract disease (HR 1.21, 95% CI 0.87-1.68). This pooled analysis of DFS and safety provides support for ICI utilization in the setting of high-risk resected MIUC.
Clinical • Retrospective data • Review • Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
2ms
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. (PubMed, Eur J Cancer)
The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • BRAF mutation • PD-L1 negative • BRAF wild-type
|
Keytruda (pembrolizumab)
2ms
Intrinsic impacts of the expression of PD-L1 on postoperative recurrence in EGFR-mutated lung adenocarcinoma. (PubMed, Front Oncol)
PD-L1 positivity emerged as an independent risk factor for RFS in patients with EGFR-mutant resected lung adenocarcinoma. These findings may provide valuable insights into the prognostic impact of PD-L1 expression and guide the implementation of postoperative adjuvant therapy in this patient population.
Journal • PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • EGFR mutation • EGFR expression • PD-L1 negative
2ms
Expression of PD-L1 in gastric cancer (ECP 2024)
The macroscopic form according to R. Borman, the morphological type according to the classification of WHO 5th edition, 2019, and the presence/absence of signet ring cells are statistically significant parameters, where there is a significant relationship with PD-L1 expression. Positive PD-L1 status is significantly more often detected in HBV-associated gastric carcinomas. An increase in the expression level of PD-L1 clones SP263 and SP142 are significant prognostic signs that reduce the likelihood of death in patients.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • PD-L1 negative
|
VENTANA PD-L1 (SP263) Assay • VENTANA PD-L1 (SP142) Assay
2ms
Deciphering the immune landscape of gastro-entero-pancreatic high-grade neuroendocrine neoplasms could help in tailoring medical treatment? (ECP 2024)
Immunotherapy has shown poor efficacy in the unselected population of HG-GEP-NENs because the immune microenvironment landscape was scant in HG-GEP-NENs at transcriptomic analysis and PD-L1 expression was absent. Thus, there is a great need to identify subsets of HG-GEP-NENs responsive to immunotherapy approaches. The present results addressed GEP-NECs with high proliferation index as sensible candidates to immunotherapy due to the enrichment in TMB-high and MSI coupled with higher CD4+ and CD8+ T cell expression.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon) • CD8 (cluster of differentiation 8) • MSH2 (MutS Homolog 2) • CD4 (CD4 Molecule)
|
PD-L1 expression • TMB-H • PD-L1 negative • POLE mutation
|
TruSight Oncology 500 Assay
2ms
Molecular diagnostic characteristics in non-small cell lung carcinomas (NSCLC) and its relationship with the PD-L1 expression (ECP 2024)
Our study showed the heterogeneity in PD-L1 expression with respect to major oncogenic drivers in Turkey. KRAS, BRAF, MET mutations and ALK and ROS1 rearrangements were more frequent, while EGFR and HER2 mutations were less frequent compared with the overall PD-L1 expression levels. Molecular testing of non-small cell lung carcinomas (NSCLC) for oncogenic driver mutations has become standard in pathology practice.
PD(L)-1 Biomarker • IO biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
PD-L1 expression • BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • PD-L1 underexpression • ALK rearrangement • MET exon 14 mutation • PD-L1 negative • ROS1 rearrangement • MET mutation
|
VENTANA PD-L1 (SP263) Assay
2ms
Clinical Significance and Molecular Annotation for PD-L1 Negative Advanced Non-Small Cell Lung Cancer with Sensitivity to Responsive to Dual PD-1/CTLA-4 Blockade. (PubMed, Immunotargets Ther)
ERBB4 and PCSK5 mutation could serve as predictive biomarkers for patients with Anti-PD-(L)1+Anti-CTLA-4 combination therapy. Our systematic nomogram demonstrates significant potential in predicting the prognosis for NSCLC patients with responsive to dual PD-1/CTLA-4 blockade.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • LTBP1 (Latent-transforming growth factor beta-binding protein 1) • ANO1 (Anoctamin 1) • COL14A1 (Collagen Type XIV Alpha 1 Chain)
|
PD-L1 expression • KRAS mutation • PD-L1 negative
2ms
Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma. (PubMed, Sci Rep)
Importantly, nonresponder patients with high prediction score turned out to have high CTLA4 expression, which suggested that neoadjuvant CTLA4 combination therapy might be effective for these patients. Our data and analysis results provide valuable insights into developing biomarkers and strategies for treating LUAD patients using immune checkpoint inhibitors.
Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
|
PD-L1 expression • PD-L1 negative • CTLA4 expression • CTLA4 underexpression
2ms
Discrepancy in PD-L1 expression between primary and metastatic tumors in two patients with recurrent cervical cancer. (PubMed, Gynecol Oncol Rep)
Pembrolizumab was added to cycle three of her systemic chemotherapy regimen of carboplatin/paclitaxel/bevacizumab. She had progression on this regimen and was transitioned to tisotumab vedotin; however, ultimately opted to proceed with hospice secondary to failure to thrive.Case 2A 36-year-old woman with history of an abnormal pap smear in pregnancy and initial biopsy demonstrating endocervical adenocarcinoma, mucinous type...This is the first case report describing these inconsistencies. Etiologies of and outcomes related to the discrepant expression of PD-L1 should be further studied.
Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 negative
|
Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Tivdak (tisotumab vedotin-tftv)
4ms
COMPARISON OF PD-L1 EXPRESSION BETWEEN PREOPERATIVE BIOPSY SPECIMENS AND SURGICAL SPECIMENS IN NON-SMALL CELL LUNG CANCER (CHEST 2024)
PD-L1 expression may differ between preoperative biopsy and surgery. CLINICAL IMPLICATIONS: When comparing the benefit of preoperative, postoperative or perioperative immunotherapy, the timing of PD-L1 expression assessment as a biomarker test for immunotherapy requires caution.
PD(L)-1 Biomarker • IO biomarker • Biopsy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative • PD-L1-L
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay
4ms
Deep Learning-based Whole Slide Image Analysis Predicts PD-L1 Status from H&E-Stained Histopathology Images in Lung Cancer (IASLC-WCLC 2024)
Characteristic Overall Training Set Testing Set N 348 279 69 sex (%) female 165 (47.69) 125 (45.13) 40 (57.97) male 181 (52.31) 152 (54.87 29 (42.03) age (%) old 188 (54.34) 158 (57.04) 30 (43.48) young 158 (45.66) 119 (42.96) 39 (56.52) Smoking (%) no 220 (86.96) 174 (86.57) 46 (88.46) yes 33 (13.04) 27 (13.43) 6 (11.54) Stage (%) I 71 (20.52) 48 (17.33) 23 (33.33) II 95 (27.46) 80 (28.88) 15 (21.74) III 168 (48.55) 139 (50.18) 29 (42.03) IV 12 (3.47) 10 (3.61) 2 (2.90) PD-L1_score (%) ≥ 50% 45 (12.93) 37 (13.26) 8 (11.59) < 1% 156 (44.83) 125 (44.80) 31 (44.93) 1-49% 147 (42.24) 117 (41.94) 30 (43.48) PD-L1_clone (%) 22C3 330 (94.83) 264 (94.62) 66 (95.65) SP142 17 (4.89) 14 (5.02) 3 (4.35) ZR3 1 (0.29) 1 (0.36) 0 (0.00) Pathology (%) LUAD 288 (83.48) 231 (83.70) 57 (82.61) LELC 9 (2.61) 4 (1.45) 5 (7.25) other 12 (3.48) 9 (3.26) 3 (4.35) LUSC 36 (10.43) 32 (11.59) 4 (5.80) Figure 1. Model Evaluation of Testing Set (A) and ROC of Two Sets (B).
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression • PD-L1 overexpression • PD-L1 negative
|
PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP142) Assay
4ms
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials (IASLC-WCLC 2024)
Baseline TCR metrics, particularly convergence, evenness, and TOP1% CS, demonstrate robust predictive value for CPR and survival in locally-advanced NSCLC patients undergoing perioperative nivolumab plus chemotherapy, warranting further investigation in larger cohorts.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • TMB-L • PD-L1 negative + TMB-L
|
Oncomine™ TCR Beta-SR Assay
|
Opdivo (nivolumab)
4ms
TCR Metrics as Predictive Biomarkers of Response and Survival after Perioperative Chemoimmunotherapy. NADIM & NADIM II Trials (IASLC-WCLC 2024)
Similar results for biomarkers were observed in NADIM and NADIM II ChIO cohorts analyzed separately, and were not predictive of patients’ outcomes when analyzed in posttreatment samples or in chemotherapy treated patients. Conclusions : Baseline TCR metrics, particularly convergence, evenness, and TOP1% CS, demonstrate robust predictive value for CPR and survival in locally-advanced NSCLC patients undergoing perioperative nivolumab plus chemotherapy, warranting further investigation in larger cohorts.
Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 negative • TMB-L • PD-L1 negative + TMB-L
|
Oncomine™ TCR Beta-SR Assay
|
Opdivo (nivolumab)
4ms
PD-L1 expression in ER-low versus triple-negative (TN) advanced breast cancer (aBC), and according to phenotypic evolution from primary to recurrent disease (ESMO 2024)
PD-L1+ status was defined as CPS≥10 (cutoff for pembrolizumab access in TN aBC). 297 patients with ER<10%/HER2- aBC were included... ER-low aBC showed a substantial PD-L1 positivity rate thus emphasizing the therapeutic deprivation in terms of ICI access that these patients are currently facing. A not negligible proportion of non-TN primary BC patients exhibited PD-L1+ status, with a remarkable rate of PD-L1+ gain during disease evolution, thus further solidifying the notion that characterization of relapsing BC can play a major role in shaping treatment access for aBC.
PD(L)-1 Biomarker • IO biomarker • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PD-1 (Programmed cell death 1)
|
PD-L1 expression • HER-2 negative • PD-L1 negative • ER negative
|
PD-L1 IHC 22C3 pharmDx
|
Keytruda (pembrolizumab)
5ms
PD-L1 expression and BRAF-TERTp signature in a continental cohort of anaplastic thyroid carcinoma (ECP 2024)
The majority of ATC are PD-L1-positive, making them candidates for anti-PD therapy. Histopathological pattern in ATC may be indicative of PD-L1 expression status. A negative PD-L1 result on needle biopsies may not preclude PD-L1 expression in other tumour foci.
PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
PD-L1 expression • BRAF V600E • BRAF V600 • PD-L1 negative • TERT mutation
|
VENTANA PD-L1 (SP263) Assay